Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study

Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study

Abstract Background Heart failure with preserved ejection fraction (HFpEF) is frequently complicated by pulmonary hypertension (PH). A pulmonary vascular contribution could be considered as a substantial therapeutic target in HFpEF and PH and combined pre- and postcapillary PH (Cpc-PH). Methods We e...

Full description

Bibliographic Details
Main Authors: Evgeny Belyavskiy, Artem Ovchinnikov, Alexandra Potekhina, Fail Ageev, Frank Edelmann
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cardiovascular Disorders
Subjects:
Pulmonary hypertension
Heart failure with preserved ejection fraction
Diastolic stress test
Diastolic dysfunction
Sildenafil
Online Access:http://link.springer.com/article/10.1186/s12872-020-01671-2

Internet

http://link.springer.com/article/10.1186/s12872-020-01671-2

Similar Items